logo image
search icon
Oncology Drug Discovery & Development Market

Oncology Drug Discovery & Development Market Size, Share & Trends Analysis Report By Drug/Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Others), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Leukemia Cancer, Lymphoma Cancer, Ovarian Cancer, Others), By Stage, By Region, And By Segment Forecasts, 2023-2031

Report ID : 2211 | Published : 2024-05-17 | Pages: 180 | Format: PDF/EXCEL

Oncology Drug Discovery & Development Market Size is predicted to witness a 18.2% CAGR during the forecast period for 2023-2031.

Key Industry Insights & Findings from the Report:

  • The increase in global cancer prevalence is a major driver for the oncology drug discovery and development market.
  • Advancements in cancer biology, genomics, and immunology are driving the oncology drug discovery and development market.
  • North America dominated the market and accounted for a global revenue share in 2023.
  • The key challenge for the oncology drug discovery and development market is the high cost and resource-intensive nature of research and development.

Oncology Drug Discovery & Development Market

Oncology drug discovery and development involve identifying and validating targets in cancer cells, discovering potential drug candidates, optimizing their properties, and conducting preclinical and clinical testing. The global increase in cancer prevalence is leading to a substantial demand for new and enhanced cancer treatments. Ongoing cancer biology, genomics, and immunology research has deepened our understanding of the disease, enabling the development of more precise and individualized therapies.

Additionally, the healthcare sector in developing nations is expanding due to a growing need for high-quality medical services, significant investments in healthcare infrastructure by governments worldwide, and the emergence of medical tourism in these regions. In light of these circumstances, it is expected that the cancer drug market will offer substantial growth prospects. Numerous drugs in the pipeline, including promising medications currently in advanced stages of development, are poised to create attractive opportunities for market expansion. Regulatory bodies have established accelerated pathways for oncology drug approvals, facilitating faster entry of promising therapies into the market.

Furthermore, the development and approval of biosimilars and generic versions of established oncology drugs introduce competition and cost-saving opportunities in the market. Moreover, the healthcare sector in developing nations is expanding due to growing demand for top-notch medical services, substantial investments in healthcare infrastructure by governments worldwide, and the rise of medical tourism in these countries. Given these circumstances, it is anticipated that the cancer drug market will have significant growth opportunities.

Competitive Landscape

Some Major Key Players In The Oncology Drug Discovery & Development Market:

  • Novartis
  • AstraZeneca
  • Merck & Co., Inc
  • Bristol-Myers Squibb
  • Pfizer,
  • Eli Lilly and Company
  • Gilead Sciences
  • Regeneron Pharmaceuticals
  • Takeda Pharmaceutical Company
  • Sanofi
  • Bayer AG
  • GlaxoSmithKline plc.
  • Genentech, Inc.
  • AbbVie Inc.
  • Others

Market Segmentation:

The oncology drug discovery & development market is segmented on the basis of drug therapy, cancer type and stage. Based on drug therapy, the market is segmented as chemotherapy, targeted therapy, immunotherapy, hormone therapy, and others. By cancer type, the oncology drug discovery & development market is categorized into lung cancer, breast cancer, colorectal cancer, prostate cancer, leukaemia cancer, lymphoma cancer, ovarian cancer, and others. By stage, the market is segmented into the discovery phase, preclinical phase, and clinical trials & others. 

Based On Product, The Targeted Therapy Segment Is Accounted As A Major Contributor In The Oncology Drug Discovery & Development Market. 

The targeted therapy category is expected to hold a major share of the global oncology drug discovery & development market in 2022. The predominance of targeted therapy can be primarily ascribed to its precision, decreased occurrence of side effects, and heightened effectiveness compared to conventional chemotherapy. Targeted therapies are meticulously designed to focus exclusively on the molecular and genetic anomalies within cancer cells, sparing healthy tissues and thereby minimizing side effects. This approach enhances patient tolerance and overall quality of life. By directly tackling the root causes of cancer while reducing the chances of organ damage and cancer reoccurrence, targeted therapy has evolved into a more patient-centred, efficient, and safer methodology.

The Breast Cancer Segment Witnessed Growth At A Rapid Rate.

The breast cancer segment is projected to grow rapidly in the global oncology drug discovery & development market. The expansion is linked to the rising incidence of reported breast cancer cases. Furthermore, the expanding population plays a role in the exploration and development of breast cancer medications. The rising occurence of breast cancer is a critical driver in oncology drug discovery and development, spurring research, innovation, and investment in the development of new therapies for breast cancer patients. It underscores the importance of addressing the specific needs of breast cancer patients within the broader oncology market.

In The Region, The North American Oncology Drug Discovery & Development Market Holds A Significant Revenue Share.

The North American oncology drug discovery & development market is anticipated to register a tremendous market share. One of the factors contributing to the increasing incidence of these diseases in Asia is the widespread use of tobacco, a known carcinogen linked to oral and laryngeal cancers and other health conditions. Regions such as Asia-Pacific, Latin America, and the Caribbean are poised for substantial growth in the near future. This growth is driven by improvements in healthcare infrastructure, increased affordability, and greater awareness regarding the significance of early cancer detection, particularly for oral cancer. In addition, the Asia Pacific region market is projected to develop faster than the global market. Moreover, the healthcare sector in developing nations is expanding due to growing demand for top-notch medical services, substantial investments in healthcare infrastructure by governments worldwide, and the rise of medical tourism in these countries. Given these circumstances, it is anticipated that the cancer drug market will have significant growth opportunities.

Recent Developments:

  • In April 2024AstraZeneca's Tigress gained FDA approval for first-line treatment of metastatic lung cancer, permitting its combination with chemotherapy. This targeted therapy can now be used alongside chemo for locally advanced or metastatic lung tumors. Additionally, recent trial findings advocate for Tigress’s earlier utilization in treatment protocols.

  • In Sept 2023, Merck KGaA (Merck) and the Institute of Cancer Research (ICR) of the United Kingdom (ICR) recommitted to their strategic partnership to explore and create novel therapeutic interventions for cancer. Collaboration will be established between Merck and researchers from the institute's Centre for Cancer Drug Discovery in order to create small-molecule inhibitors of a novel class of cancer targets. Both parties will contribute personnel and financial resources to the multi-year, multi-goal partnership. 

Oncology Drug Discovery & Development Market Report Scope

Report Attribute

Specifications

Growth Rate CAGR

CAGR of 18.2% from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Application, Technology, Installation Type, Vessel Type

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Competitive Landscape

Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead Sciences, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, Sanofi, Bayer AG, GlaxoSmithKline plc., Genentech, Inc., AbbVie Inc and among others.

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Oncology Drug Discovery & Development Market Snapshot

Chapter 4. Global Oncology Drug Discovery & Development Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Drug/Therapy Type Estimates & Trend Analysis

5.1. By Drug/Therapy Type, & Market Share, 2020 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Drug/Therapy Type:

5.2.1. Chemotherapy

5.2.2. Targeted Therapy

5.2.3. Immunotherapy

5.2.4. Hormone Therapy

5.2.5. Others

Chapter 6. Market Segmentation 2: By Cancer Type Estimates & Trend Analysis

6.1. By Cancer Type & Market Share, 2020 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Cancer Type:

6.2.1. Lung Cancer

6.2.2. Breast Cancer

6.2.3. Colorectal Cancer

6.2.4. Prostate Cancer

6.2.5. Leukemia Cancer

6.2.6. Lymphoma Cancer

6.2.7. Ovarian Cancer

6.2.8. Others

Chapter 7. Market Segmentation 3: By Stage Estimates & Trend Analysis

7.1. By Stage & Market Share, 2020 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Stage:

7.2.1. Discovery Phase

7.2.2. Preclinical Phase

7.2.3. Clinical Trials

7.2.4. Others

Chapter 8. Oncology Drug Discovery & Development Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Oncology Drug Discovery & Development Market revenue (US$ Million) estimates and forecasts By Drug/Therapy Type, 2019-2031

8.1.2. North America Oncology Drug Discovery & Development Market revenue (US$ Million) estimates and forecasts By Cancer Type, 2019-2031

8.1.3. North America Oncology Drug Discovery & Development Market revenue (US$ Million) estimates and forecasts By Stage, 2019-2031

8.1.4. North America Oncology Drug Discovery & Development Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

8.2. Europe

8.2.1. Europe Oncology Drug Discovery & Development Market revenue (US$ Million) By Drug/Therapy Type, 2019-2031

8.2.2. Europe Oncology Drug Discovery & Development Market revenue (US$ Million) By Cancer Type, 2019-2031

8.2.3. Europe Oncology Drug Discovery & Development Market revenue (US$ Million) By Stage, 2019-2031

8.2.4. Europe Oncology Drug Discovery & Development Market revenue (US$ Million) by country, 2019-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Oncology Drug Discovery & Development Market revenue (US$ Million) By Drug/Therapy Type, 2019-2031

8.3.2. Asia Pacific Oncology Drug Discovery & Development Market revenue (US$ Million) By Cancer Type, 2019-2031

8.3.3. Asia Pacific Oncology Drug Discovery & Development Market revenue (US$ Million) By Stage, 2019-2031

8.3.4. Asia Pacific Oncology Drug Discovery & Development Market revenue (US$ Million) by country, 2019-2031

8.4. Latin America

8.4.1. Latin America Oncology Drug Discovery & Development Market revenue (US$ Million) By Drug/Therapy Type, (US$ Million) 2019-2031

8.4.2. Latin America Oncology Drug Discovery & Development Market revenue (US$ Million) By Cancer Type, (US$ Million) 2019-2031

8.4.3. Latin America Oncology Drug Discovery & Development Market revenue (US$ Million) By Stage, (US$ Million) 2019-2031

8.4.4. Latin America Oncology Drug Discovery & Development Market revenue (US$ Million) by country, 2019-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Oncology Drug Discovery & Development Market revenue (US$ Million) By Drug/Therapy Type, (US$ Million) 2019-2031

8.5.2. Middle East & Africa Oncology Drug Discovery & Development Market revenue (US$ Million) By Cancer Type, (US$ Million) 2019-2031

8.5.3. Middle East & Africa Oncology Drug Discovery & Development Market revenue (US$ Million) By Stage, (US$ Million) 2019-2031

8.5.4. Middle East & Africa Oncology Drug Discovery & Development Market revenue (US$ Million) by country, 2019-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. F. Hoffmann-La Roche Ltd,

9.2.2. Novartis,

9.2.3. AstraZeneca,

9.2.4. Merck & Co., Inc,

9.2.5. Bristol-Myers Squibb,

9.2.6. Pfizer,

9.2.7. Eli Lilly and Company,

9.2.8. Gilead Sciences,

9.2.9. Regeneron Pharmaceuticals,

9.2.10. Takeda Pharmaceutical Company,

9.2.11. others 

Segmentation Of Oncology Drug Discovery & Development Market-

Oncology Drug Discovery & Development Market By Drug/Therapy

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormone Therapy
  • Others

Oncology Drug Discovery & Development Market Seg

Oncology Drug Discovery & Development Market By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Leukemia Cancer
  • Lymphoma Cancer
  • Ovarian Cancer
  • Others

Oncology Drug Discovery & Development Market By Stage

  • Discovery Phase
  • Preclinical Phase
  • Clinical Trials & Others

Oncology Drug Discovery & Development Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

What is the Oncology Drug Discovery & Development Market Growth?

Takeda Pharmaceutical Company, Sanofi, Bayer AG, GlaxoSmithKline plc., Genentech, Inc., AbbVie Inc and among others.

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach